Elvia Moreta Freire, MD
Rheumatology · Eagan, MNNPI 1275566929
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (44.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Argenx US, Inc. at 27.6% of the total.
Across 51 payments — averaging $143.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$2K
- Fresenius Kabi USA, LLC$2K
- Janssen Research & Development, LLC$1K
- Johnson & Johnson$845
- Janssen Scientific Affairs, LLC$409
- Gilead$390
- plus $750 from 11 others
Across 103 payments — averaging $7702.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$344K
- E.r. Squibb & Sons, L.L.C.$249K
- Eli Lilly$141K
- AbbVie$51K
- GSK$4K
- Argenx US, Inc.$4K
- plus $1K from 2 others
What the payments were for
- Consulting fees$2,31031%
- Grants$2403%
- Travel & lodging$3,22844%
- Food & beverage$1,52821%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 3 | $2,028 |
| Fresenius Kabi USA, LLC | 1 | $1,560 |
| Janssen Research & Development, LLC | 9 | $1,354 |
| Johnson & Johnson | 7 | $845 |
| Janssen Scientific Affairs, LLC | 3 | $409 |
| Gilead | 1 | $390 |
| AbbVie | 6 | $294 |
| E.r. Squibb & Sons, L.L.C. | 2 | $157 |
| Amgen(2 entities) | 5 | $76 |
| Aurinia Pharma U.S., Inc. | 5 | $72 |
| AstraZeneca(2 entities) | 3 | $43 |
| Boehringer Ingelheim | 1 | $28 |
| Bioventus LLC | 1 | $24 |
| Sanofi | 1 | $17 |
| Pfizer | 1 | $13 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
| Radius Health, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART$2,028
- Tremfya$1,159
- STELARA$750
- SIMPONI ARIA$750
- Rinvoq$240
How this compares
$7,335 in reported general payments places this provider in the 85th percentile of 121 rheumatology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MethotrexateMethotrexate Sodium | 46 | $1,977 |
| Pilocarpine Hcl | 13 | $1,668 |
| Hydroxychloroquine Sulfate | 18 | $1,050 |
| Nabumetone | 13 | $381 |
| Gabapentin | 11 | $270 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Eagan
- David RidleyEagan$26K
- Asim KhanMaple Grove$1.2M
- Parastoo FazeliMinneapolis$149K
- Robert TierneySt Louis Park$137K
- Ali SajjadMaplewood$87K
- Steven YtterbergRochester$87K
- Cornelia WeyandRochester$59K
- Eric MattesonRochester$51K
- Jeffrey WilsonEdina$49K
- John DavisRochester$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.